The genome-wide association studies have identified a strong association between interleukin 28B (IL28B) gene polymorphisms and the response to treatment in patients with hepatitis C virus (HCV) infection. The aim of the study was to evaluate the association between three most widely studied IL28B gene polymorphisms and the response to antiviral treatment of chronic hepatitis C. We performed the genotyping of the three IL28B gene polymorphisms: rs12979860, rs8099917, and rs12980275 in 72 Caucasian patients with chronic hepatitis C, previously treated with the combination therapy of pegylated interferon alpha (PEGIFN α) and ribavirin (RBV). The patients included in the study had finished the treatment regimen at least 6 months before enrolling in the study. We used the sustained viral response (SVR) for the evaluation of the effectiveness of the antiviral treatment, and it was tested with an assay with a sensitivity of 20 IU/mL. An SVR was achieved in 59.7% (43/72) of the treated patients. The three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA genotype of rs12980275) were associated with the SVR (p=0.029, p=0.016, and p=0.028, respectively) in the study patients with chronic hepatitis C treated with the combination therapy of PEGIFN α and RBV. The association of IL28B gene polymorphisms with the treatment response points to the possibility of personalized medicine for the treatment of HCV infection.
Introduction: IP-10 it has been studied as a predictor of treatment response in chronic HCV infected patients. The data for the HBV infection are not enough.Aim: To compare IP-10 levels in patients with chronic HBV /CHB/ and HCV infection /CHC/ and their relation to liver disease and treatment response. Material and methods: 20 patients - with CHC genotype 1 infection /on standard bi-therapy/ and 32 patients with CHB /21 pts - NUC; 11 pts - IFN/. Results: The IP-10 did not correlate with sex, age, ALT and liver fibrosis. The basal IP-10 were lower in patients with CHB (p=0,017). There was a difference in IP-10 baseline levels among the HCV patients with or without RVR (p=0,007). A negative correlation was found between basal IP-10 and RVR (r= -0,508; p=0,008). Conclusion: IP-10 could predict virological response in patients with CHC on standard bi-therapy, but not in HBV infected patients on standard therapy
Serum surface antigen of the hepatitis B virus (HBsAg) level has been recently introduced and studied during the last years as a simple and non-invasive serum surrogate marker for covalently closed circular DNA (cccDNA). The aim of the present study was to evaluate the serum HBsAg levels in Bulgarian patients during the first 12 months of therapy with nucleoside/nucleotide analogues (NUC). Twenty patients with chronic hepatitis B (CHB) infection were studied. Initially, 9 out of the 20 subjects were Hepatitis B 'e' antigen (HBeAg)-positive and 11 were HBeAg-negative. Serum hepatitis B virus DNA (HBV DNA), as well as serum HBsAg levels were measured prior therapy and after 3 and 12 months of treatment. The baseline HBsAg levels in HBeAg-positive patients were more than three times higher, compared to HBeAg-negative subjects. We found an initial slight increase of HBsAg in 2/9 HBeAg-positive patients and in 3/11 HBeAg-negative subjects. A positive correlation was found between baseline HBsAg and HBV DNA. A rapid decline of HBsAg levels was observed in one-third of the HBeAg-positive patients at the 12th month of treatment. In the HBeAgnegative patients, HBsAg levels remained relatively unchanged. Measurement of HBsAg levels during NUC therapy is not used routinely. After achieving a persistently undetectable serum HBV DNA and normal aminotransferase levels, HBsAg level remains an important surrogate marker for the course of the liver disease. The HBsAg levels, together with HBV DNA, may provide essential additional information and may help to define and evaluate the upcoming new therapeutic strategies.
When a sensitive RT-PCR assay was applied, to determine if treatment induced clearance of HCV infection had been successful, occult hepatitis C could not be detected by an ultrasensitive assay, neither in HD nor in non-renal patients.
IntroductionHepatocellular carcinoma (HCC) represents more than 90% of primary liver cancers and is a major global health problem. In the era of Direct acting agents (DAA) for treatment of hepatitis C virus (HCV), sustained virological response (SVR) is achieved in more than 80% of cases. Accumulating clinical experience of DAA-based treatment has suggested that post-SVR HCC development and recurrence may be more frequent compared to interferon (IFN)-based treatment. We describe a case of poor differentiated HCC in non-cirrhotic liver, after HCV-eradication. Case presentation:A 73-year-old female presented with HCV-hepatitis at the beginning of 2017. A liver biopsy showed low grade fibrosis (F1). HCV genotype was 1b, with viral load 680 500 IU/ml. She was anti-HBc total positive, but negative for hepatitis B surface antigen (HBsAg) and HBV DNAnegative, and also anti-HIV 1/2 and had no history of alcohol or drug abuse. In May 2017 -treatment with IFN-free regime was started -3D -Viekirax and Exviera, without Ribavirin. At the 4th week of treatment HCV RNA was negative. At the 12th week abdominal ultrasound (US) showed a 60 mm liver nodule in 6th segment and a few more nodules form 10 to 32 mm. AFP was slightly elevated (59 ng/ml). Original ArticleMedInform I S S U E 2 , 2 0 1 8 MedInformThe contrast enhanced computed tomography (CT) scan showed typical signs of HCC. Ultra sound (US)-guided biopsy was performed. Histological result was: Anaplastic carcinoma with stromal desmoplasia and expressed lymphocyte stromal reaction (a liver origin is possible). Immunohistochemistry test showed: Alpha-feto protein -negative reaction; Ca 19-9 -negative reaction, but Ki67 -40% proliferative activity. The patient was at stage B according to Barcelona-clinic liver cancer (BCLC) classification and treatment with Sorafenib was started. Discussion:Sequence of chronic hepatitis -cirrhosis -HCC is well known. In these cases the major role in oncogenesis is due to severe fibrosis and inflammation. HCC in non-cirrhotic liver is not well understood.The oncogenic potential of core protein of HCV has been discussed and therefore HCV is directly involved in hepatocarcinogenesis. Recent studies show higher frequency of HCC in patients with 1b HCV infection. In presented case -the patient was infected with HCV subgenotype 1b and had very low stage of fibrosis. But she was anti HBcor -positive and after HCV eradication. Several studies suggested a possibly distinct difference in host immune modulation between interferon and DAAs.Because of multiple character of HCC (more than 3 nodule, exactly 7 in this case), the initial treatment was Sorafenib. It was well tolerated and resent CT showed only two nodules. In this stage a RFTA is discussing.
Background: It has been shown that single nucleotide polymorphisms (SNPs) near the interleukin 28B (IL28B) gene were associated with sustained viral response following standard treatment of hepatitis C virus infection. Aim:The aim of the study was to evaluate the association between the SNPs near the IL28B gene and the response to the treatment of chronic hepatitis C. Methods:The genotyping of the three IL28B gene polymorphisms: rs12979860, rs8099917, and rs12980275 was done in 100 Caucasian patients with chronic hepatitis C previously treated with standard antiviral therapy. The study group consisted of 28 hemodialysis patients with end stage renal disease treated with pegylated interferon α and 72 patients without renal disease treated with pegylated interferon α and ribavirin. All patients finished the antiviral treatment at least 6 months before enrollment in the study. Sustained viral response, defined as an absence of detectable HCV RNA in the serum, was tested by an assay with a sensitivity of 20 IU/mL.Results: Sustained viral response was achieved in 56% (56/100) of the treated patients. The three IL28B gene polymorphisms (CC genotype of rs12979860, TT genotype of rs8099917, and AA genotype of rs12980275) were associated with sustained viral response (p=0.006, p=0.002, p=0.007, respectively) in study patients with chronic hepatitis C treated with standard antiviral therapy. Conclusion:The IL28B gene polymorphisms: rs12979860, rs8099917, and rs12980275 were significantly associated with the successful treatment of chronic hepatitis C.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.